IceCure Medical, developer of the ProSense system, a minimally-invasive cryoablation technology that destroys tumours by freezing as an alternative to surgical tumour removal, has announced that Health Canada, the Canadian government’s regulatory agency, has approved the system, its disposable cryoprobes, and introducers as cryosurgical tools.
The approval comes for indications including tumours, allowing the ablation of benign and malignant tumours of the lung, liver, kidneys, and musculoskeletal system, and benign tumours of the breast. It is also indicated for general surgery, palliative intervention, and other surgeries.
“As we continue to gain traction in the United States, this approval in Canada will create synergies for us in the broader North American market,” stated IceCure CEO, Eyal Shamir. “We have been directly engaging with healthcare providers through education, hands-on training seminars, marketing, and sales in the US and we will expand these activities into Canada. We have already been contacted by multiple Canadian healthcare providers with requests to purchase and implement ProSense.”
IceCure’s cryoablation system currently has regulatory approval for various indications in 15 countries, including in the US, China and European nations.
